Home » Stocks & Shares » GSK share price: Pharmco still struggles to turn profits into cash

GSK share price: Pharmco still struggles to turn profits into cash

Tsveta van Son
  • May 3rd 2019, 07:21
  • Last Updated: September 17th 2019, 14:59

Hargreaves Lansdown reckons that while GlaxoSmithKline (LON:GSK) has delivered profits ahead of expectations, it is still struggling to turn them into cash, Citywire reports. The comments came after the blue-chip drugmaker posted a rise in sales and earnings earlier this week, having benefitted from strong demand for its vaccines and HIV treatments.

GSK’s share price closed lower yesterday, giving up 0.79 percent to 1,547.40p, underperforming the broader UK market, with the benchmark FTSE 100 index closing 0.46 percent in the red at 7,351.31 points. This morning, the shares have been little changed, having inched 0.04 percent to 1,548.00p as of 08:16 BST, as compared with a 0.2-percent gain in the Footsie.

HL weighs in on GSK

Citywire quoted Hargreaves Lansdown analyst Nicholas Hyett as commenting that GSK’s cash conversion had “deteriorated significantly, partly down to timing, but also because headline profitability is being flattered by revaluations that don’t turn up in the all-important cashflow statement”. The comments came even as the blue-chip drugmaker posted a rise in product sales for the first quarter.

Hyett, however, reckons that investors should give the pharma giant ‘the benefit of the doubt, at least for now’, as product launches have performed well and the labs are busy. The pharmco’s chief executive Emma Walmsley said in the company’s results statement this week that “strengthening the company’s pipeline remained GSK’s number one priority”.

GSK meanwhile continues to expect a decline in full-year earnings as a generic version of its respiratory drug Advair hit the US market.

Other analysts on group

UBS reaffirmed the blue-chip pharmco as ‘neutral’ yesterday, with a target of 1,630p on the GSK share price, while Credit Suisse, which is also ‘neutral’ on the stock, set a valuation of 1,600p. According to MarketBeat, the FTSE 100 drugmaker currently has a consensus ‘hold’ rating and an average price target of 1,524.57p.

About the author

Tsveta van Son
Tsveta van Son is part of Invezz’s journalist team. She has a BA degree in European Studies and a MA degree in Nordic Studies from Sofia University and has also attended the University of Iceland. While she covers a variety of investment news, she is particularly interested in developments in the field of renewable energy.

Leave a Reply

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.